Overview

A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-10-15

Target enrollment:

Participant gender:

Summary

The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time. Researchers will compare what happens to MK-5684 after hemodialysis in people with severe renal impairment and end-stage renal disease versus healthy people.

Phase:

PHASE1

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

fludrocortisone acetate
Prednisone